Z
ZENTALIS PHARMACEUTICALS LLC
NASDAQ: ZNTL (Zentalis Pharmaceuticals, Inc.)
Last update: 2 hours ago3.11
0.03 (0.97%)
| Previous Close | 3.08 |
| Volume | 1,259,730 |
| Price / Sales | 7.13 |
| Price / Book | 2.05 |
| 52 Weeks Range |
| Operating Margin (TTM) | -746.40% |
| Diluted EPS (TTM) | -3.14 |
| Total Debt/Equity (MRQ) | 14.27% |
| Current Ratio (MRQ) | 6.94 |
| Operating Cash Flow (TTM) | -151.52 M |
| Levered Free Cash Flow (TTM) | -79.27 M |
| Return on Assets (TTM) | -26.62% |
| Return on Equity (TTM) | -59.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Zentalis Pharmaceuticals, Inc. | Mixed | Bearish |
AIStockmoo Score
-2.0
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | -0.5 |
| Average | -2.00 |
|
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 13.58% |
| % Held by Institutions | 80.34% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| 5Am Venture Management, Llc | 30 Jun 2026 | 3,947,913 |
| Squadron Capital Management Llc | 30 Jun 2026 | 3,700,000 |
| Acadian Asset Management Llc | 30 Jun 2026 | 2,681,900 |
| Two Sigma Advisers, Lp | 31 Dec 2025 | 1,483,500 |
| Opaleye Management Inc. | 30 Jun 2026 | 1,412,656 |
| Orbimed Advisors Llc | 30 Jun 2026 | 1,390,576 |
| Decheng Capital Llc | 30 Jun 2026 | 1,323,327 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |